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Daratumumab, a CD38 human monoclonal antibody, demonstrat-ed significant clinical activity in combination with bortezomiband dexamethasone versus bortezomib and dexamethasone alone
in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
refractory multiple myeloma. A post hoc analysis based on treatment his-
tory and longer follow up is presented. After 19.4 (range: 0-27.7) months
of median follow up, daratumumab plus bortezomib and dexametha-
sone prolonged progression-free survival (median: 16.7 versus 7.1
months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; 
P<0.0001) and improved the overall response rate (83.8% versus 63.2%;
P<0.0001) compared with bortezomib and dexamethasone alone. The
progression-free survival benefit of daratumumab plus bortezomib and
dexamethasone was most apparent in patients with 1 prior line of ther-
apy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% con-
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ABSTRACT
Introduction
As multiple myeloma (MM) progresses, a reduction in
the duration and depth of response is observed with each
treatment relapse, as a result of diminished sensitivity of
heavily treated patients to subsequent therapies.1 
Proteasome inhibitors (PIs) are widely used due to their
clinical effectiveness, manageable safety profile, and com-
binability with other therapies.2 However, in several stud-
ies of novel PI-based regimens in relapsed and/or refracto-
ry MM (RRMM), deep clinical responses were uncom-
mon.3-6 PI-based regimens that generate deeper responses
in RRMM are an unmet need. 
Daratumumab, a human IgGκmonoclonal antibody tar-
geting CD38, has a direct on-tumor and immunomodula-
tory mechanism of action.7-12 In combination with stan-
dard of care regimens, (bortezomib and dexamethasone
[Vd; CASTOR] or lenalidomide and dexamethasone [Rd;
POLLUX]), daratumumab induced rapid, deep, and
durable responses, reducing the risk of disease progression
or death by >60%, versus Vd or Rd in relapsed patients.13,14
Based on the superior progression-free survival (PFS) ben-
efit, daratumumab-Vd (D-Vd) and daratumumab-Rd 
(D-Rd) were approved in the United States and Europe for
MM patients who have received ≥1 prior therapy.15,16 In
addition, daratumumab plus pomalidomide and dexam-
ethasone was approved in the United States for MM
patients after 2 prior therapies including lenalidomide and
a PI.15 More recently, daratumumab in combination with
bortezomib, melphalan, and prednisone was approved in
the United States for patients with newly diagnosed MM
who are ineligible for autologous stem cell transplanta-
tion.15
At the time of the event-driven, pre-specified primary
analysis (median follow up: 7.4 months) of the CASTOR
study, PFS was significantly prolonged with D-Vd versus
Vd (median: not reached versus 7.2 months; hazard ratio
[HR], 0.39; 95% confidence interval [CI], 0.28-0.53; 
P<0.0001).13 This updated analysis provides an additional
12 months of follow up for efficacy and safety compared
with the primary analysis, including updated PFS in the
intent-to-treat (ITT) population, and presents an
exploratory post hoc analysis of CASTOR to identify
patient subgroups that may benefit most from D-Vd. 
Methods
Study Design
CASTOR (clinicaltrials.gov identifier: 02136134) is an
ongoing multi-center, open-label, randomized, active-con-
trolled, phase 3 study of D-Vd versus Vd in patients with
RRMM who received ≥1 prior line of therapy. The study
design and primary results were previously published.13
Briefly, patients were randomized 1:1 to D-Vd or Vd.
Randomization was balanced and stratified by
International Staging System (I, II, or III) at screening (cen-
tral laboratory results), number of prior lines of therapy (1
versus 2 or 3 versus >3), and prior bortezomib exposure (no
versus yes). The study protocol was approved by an inde-
pendent ethics committee or institutional review board at
each study center, and was conducted in accordance with
the principles of the Declaration of Helsinki and the
International Conference on Harmonisation Good Clinical
Practice guidelines. All patients provided written informed
consent. 
Patients
Eligible patients had ≥1 prior line of therapy, achieved at
least a partial response to ≥1 prior MM treatment, and had
progressive disease per International Myeloma Working
Group (IMWG) criteria17,18 on or after their last regimen.
Patients refractory to bortezomib or another PI (ixazomib
or carfilzomib following a protocol amendment) were
ineligible.
Procedures
Patients received 8 cycles of bortezomib (1.3 mg/m2 sub-
cutaneously on Days 1, 4, 8, 11) and dexamethasone 
(20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, 12) with or with-
out daratumumab (16 mg/kg intravenously once weekly
in Cycles 1-3, Day 1 of Cycles 4-8, then every 4 weeks
until disease progression, unacceptable toxicity, or with-
drawal of consent). Cycle durations were 21 days for
Cycles 1 to 8 and 28 days for Cycle 9 onwards. A protocol
amendment after the primary analysis allowed patients
who progressed on Vd to receive daratumumab
monotherapy.
Assessments and Endpoints
The primary endpoint was PFS; secondary endpoints
included time to disease progression, overall response rate
(ORR), minimal residual disease (MRD), and safety. This
exploratory, post hoc, secondary analysis examined sub-
populations according to prior lines of therapy (1, 2-3, >3,
or 1-3), prior treatment exposure (bortezomib, thalido-
mide, or lenalidomide), refractoriness to lenalidomide at
the last prior line of therapy, time since last therapy (≤12,
>12, ≤6, or >6 months), and cytogenetic risk assessed cen-
trally by next-generation sequencing.19 Site investigators
determined numbers of prior lines of therapy using
IMWG guidelines.18 Time since last therapy was the dura-
tion between the end date of the last line of prior therapy
and the randomization date. PFS, ORR, and MRD-nega-
tivity at 10–5 and 10–6 sensitivity thresholds were assessed
for each subgroup. PFS based on MRD (10–5), and cytoge-
netic risk status was also examined. Health-related quality
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fidence interval, 0.12-0.29; P<0.0001). Daratumumab plus bortezomib and dexamethasone was also
superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure
(bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (≤12,
>12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold high-
er with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dex-
amethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexam-
ethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the
greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.  
of life (HRQoL) was assessed by the European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core-30 (EORTC QLQ-
C30) and the EuroQol 5 Dimensions Questionnaire (EQ-
5D-5L) tools.
The Online Supplementary Appendix provides full details
of statistical analyses and MRD, cytogenetic, and HRQoL
assessments.
Results 
Of 498 patients, 251 and 247 were randomized to D-Vd
and Vd, respectively (Online Supplementary Figure S1).
Patient demographics and baseline clinical characteristics
were previously published and are well-balanced between
groups.13 Relevant clinical characteristics, including treat-
ment history and cytogenetic-risk status, were balanced
between groups and are summarized in Table 1 and Online
Supplementary Table S1. Briefly, patients in CASTOR
received a median of 2 prior lines of therapy. Overall,
47.2% received 1 prior line of therapy, 28.9% received 2
prior lines, 13.9% received 3 prior lines, and 10.0%
received >3 prior lines of therapy. A total of 21.1% of
patients were refractory to lenalidomide at their last line
of therapy. 
Among patients treated with D-Vd, the median dura-
tion of treatment was 13.4 months (range: 0-26.7) versus
5.2 months (range: 0.2-8.0) with Vd. Following a protocol
amendment after the primary analysis, patients who pro-
gressed on Vd had the option to receive daratumumab
monotherapy.13 At a median follow up of 19.4 months, all
patients in both groups had discontinued or completed Vd
treatment per protocol; in the D-Vd group, 41% of
patients remained on daratumumab monotherapy. A total
of 64 patients in the Vd group opted to receive daratu-
mumab monotherapy following disease progression.
The clinical cut-off date was January 11, 2017. At a
median duration of follow up of 19.4 months (range: 0-
27.7), D-Vd significantly prolonged PFS versus Vd (median:
16.7 versus 7.1 months; HR, 0.31; 95% CI, 0.24-0.39;
P<0.0001 [Figure 1A]), with 18-month PFS rates of 48.0%
and 7.9%, respectively. Among response-evaluable
patients (D-Vd, n=240; Vd, n=234), ORR was significantly
improved with D-Vd versus Vd (83.8% versus 63.2%;
P<0.0001 [Table 2]), including higher rates of stringent
complete response (CR) (8.8% versus 2.6%), CR or better
(28.8% versus 9.8%; P<0.0001), and very good partial
response or better (62.1% versus 29.1%; P<0.0001 [Online
Supplementary Table S2]). 
MRD was evaluated for the ITT population at pre-spec-
ified time points using a stringent, unbiased approach
with IMWG criteria of a minimum sensitivity threshold of
10–5 for next-generation sequencing evaluation.20 At this
threshold, 11.6% of D-Vd–treated patients were MRD-
negative versus 2.4% of Vd-treated patients 
(P=0.000034 [Table 2]). Consistent findings were observed
at a higher sensitivity threshold of 10–6 (D-Vd: 4.8%; Vd:
0.8%; P=0.004763). Overall survival (OS) remained imma-
ture at the time of this analysis, and survival follow up will
continue until 320 deaths are reported, per protocol. 
Subgroup analyses showed the clinical benefit of dara-
tumumab by prolonging PFS and improving ORR and
MRD negativity across all clinical populations (Table 2
and Figure 2). Patients who received D-Vd at first relapse
(D-Vd, n=122; Vd, n=113) achieved the greatest benefit
(Table 2 and Figure 2). In this population, PFS was signifi-
cantly prolonged with D-Vd versus Vd (median: not
reached versus 7.9 months; HR, 0.19; 95% CI, 0.12-0.29;
P<0.0001 [Figure 1B]), an 81% reduction in the risk of dis-
ease progression or death with 18-month PFS of 68.0%
versus 11.5%, respectively. Among patients with 2 to 3
prior lines of therapy (D-Vd, n=107; Vd, n=106), PFS was
also significantly prolonged with D-Vd versus Vd (median:
9.8 versus 6.3 months; HR, 0.51; 95% CI, 0.36-0.71; 
P<0.0001), with 18-month PFS of 31.2% versus 5.5%,
respectively (Figure 1C). Likewise, in patients with 1 to 3
prior lines of therapy (D-Vd, n=229; Vd, n=219), D-Vd sig-
nificantly prolonged PFS versus Vd (median: 18.9 versus 7.3
months; HR, 0.31; 95% CI, 0.24-0.40; P<0.0001), with 18-
month PFS rates of 51.2% versus 8.7%, respectively
(Online Supplementary Figure S2).
Subgroup analyses of CASTOR
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Table 1. Baseline demographics and clinical characteristics of the ITT
population.
Characteristic D-Vd Vd
n=251 n=247
Age (years)
Median (range) 64 (30-88) 64 (33-85)
Median time from diagnosis (years) 3.9 3.7
Number of prior lines of therapy, n (%)
Median (range) 2 (1-9) 2 (1-10)
1 122 (48.6) 113 (45.7)
2-3 107 (42.6) 106 (42.9)
>3 22 (8.8) 28 (11.3)
1-3 229 (91.2) 219 (88.7)
Prior treatments, n (%)
PI 169 (67.3) 172 (69.6)
Bortezomib 162 (64.5) 164 (66.4)
IMiD 179 (71.3) 198 (80.2)
Thalidomide 125 (49.8) 121 (49.0)
Lenalidomide 89 (35.5) 120 (48.6)
PI and IMiD 112 (44.6) 129 (52.2)
Prior ASCT, n (%) 157 (62.5) 149 (60.3)
Refractory to last line of therapy, n (%) 76 (30.3) 85 (34.4)
Refractory to lenalidomide at last 45 (17.9) 60 (24.3)
prior line of therapy, n (%)
Treatment-free interval, n (%) 
>12 months 118 (47.0) 104 (42.1)
≤12 months 133 (53.0) 143 (57.9)
>6 months 150 (59.8) 133 (53.8)
≤6 months 101 (40.2) 114 (46.2)
Cytogenetic profile, n (%)a
n 167 186
Standard-risk 123 (73.7) 135 (72.6)
High-risk 44 (26.3) 51 (27.4)
ITT: intent-to-treat; D-Vd: daratumumab plus bortezomib and dexamethasone; Vd:
bortezomib and dexamethasone; PI: proteasome inhibitor; IMiD: immunomodulatory
drug; ASCT: autologous stem cell transplantation; data are median (range) or n (%).
aCytogenetic status was determined using next-generation sequencing. High-risk cyto-
genetic status was defined as having ≥1 of the following abnormalities: del17p, t(4;14),
or t(14;16); standard-risk cytogenetic status was defined as those who underwent cyto-
genetic testing and did not meet the high-risk criteria.
The PFS benefit of daratumumab was maintained in
patients who received prior bortezomib (D-Vd, n=162;
Vd, n=164; median: 12.1 versus 6.7 months; HR, 0.35; 95%
CI, 0.26-0.46; P<0.0001 [Online Supplementary Figure S3]),
with 18-month PFS rates of 37.9% and 1.8%, respectively.
In this subgroup, D-Vd improved ORR (80.5% versus
59.5%) and increased MRD-negative rates (6.2% versus
0.6%) versus Vd (Table 2). Importantly, the PFS benefit of
daratumumab was maintained in patients who received
prior bortezomib in their only line of therapy (D-Vd,
n=62; Vd, n=57; median: 19.6 versus 8.0 months; HR, 0.20;
95% CI, 0.12-0.35; P<0.0001 [Online Supplementary Figure
S4]), with 18-month PFS rates of 58.1% and 2.1%, respec-
tively.
Patients refractory to lenalidomide at their last prior line
of therapy (D-Vd, n=45; Vd, n=60) also achieved a signifi-
cant PFS benefit with D-Vd versus Vd (median: 9.3 versus
4.4 months; HR, 0.36; 95% CI, 0.21-0.63; P=0.0002 [Figure
2]), with 18-month PFS rates of 33.5% versus 2.0%, respec-
tively. In this subgroup, D-Vd improved ORR (80.5% ver-
sus 50.0%) and increased MRD negativity (8.9% versus
0%) versus Vd (Table 2).
In a pre-specified subgroup analysis of cytogenetic risk,
D-Vd prolonged PFS and improved ORR versus Vd (Table
2, Figures 2 and 3A). PFS was prolonged with D-Vd versus
Vd in both high-risk (median: 11.2 versus 7.2 months; HR,
0.45; 95% CI, 0.25-0.80; P=0.0053; D-Vd, n=44; Vd, n=51)
and standard-risk disease (median: 19.6 versus 7.0 months;
HR, 0.26; 95% CI, 0.18-0.37; P<0.0001; D-Vd, n=123; Vd,
n=135 [Figures 2 and 3A]). ORRs were higher with D-Vd
for both high-risk (D-Vd, n=44; Vd, n=47; 81.8% versus
61.7%; P=0.2028) and standard-risk (D-Vd, n=118; Vd,
n=131; 84.7% versus 64.1%; P=0.0001) subgroups (Table
2). Higher D-Vd response rates aligned with MRD nega-
tivity. In the D-Vd group, 13.8% (17/123) of evaluable,
standard-risk patients reached MRD negativity at 10–5 sen-
sitivity versus 2.2% (3/135) in the Vd group (P=0.0003
[Table 2]). No high-risk Vd group patients (n=51) achieved
MRD negativity at 10–5, unlike 13.6% (6/44) of high-risk
D-Vd group patients (P=0.0018). The PFS benefit of D-Vd
versus Vd was also maintained irrespective of the time
since last therapy (≤12, >12, ≤6, or >6 months [Figure 2]).
Regardless of treatment group, PFS was prolonged in
patients who achieved MRD-negative status (median: not
reached in either group [Figure 3B]). Conversely, among
patients with MRD-positive status (10–5), D-Vd significant-
A. Spencer et al.
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Figure 1. PFS (A) in the ITT population and (B) in patients who received 1
prior line of therapy or (C) 2 to 3 prior lines of therapy. Kaplan-Meier esti-
mates of PFS. PFS: progression-free survival; ITT: intent-to-treat; D-Vd: dara-
tumumab plus bortezomib and dexamethasone; Vd: bortezomib and dex-
amethasone; HR: hazard ratio; CI: confidence interval. 
A B
C
ly prolonged PFS versus Vd (median: not reached versus
16.2 months; HR, 0.19; 95% CI, 0.05-0.73; P=0.0080
[Figure 3B]). The rate of MRD negativity (10–5) continued
to increase over time for patients in the overall study pop-
ulation who received D-Vd versus Vd (Figure 4).
Within the safety population (D-Vd, n=243; Vd, n=237),
longer follow up revealed a tolerability profile consistent
with the primary analysis and no new emergent toxicities.
Among the most common (≥15%) hematologic treat-
ment-emergent adverse events (TEAEs) were thrombocy-
topenia and anemia. Among the most common (≥15%)
non-hematologic TEAEs were peripheral sensory neu-
ropathy, diarrhea, upper respiratory tract infection, and
cough (Table 3). 
The most common (≥5%) grade 3 or 4 hematologic
TEAEs included thrombocytopenia, anemia, neutropenia,
and lymphopenia (Table 3). The most common (≥5%)
grade 3 or 4 non-hematologic TEAEs included pneumonia,
hypertension, and peripheral sensory neuropathy.
Discontinuations due to TEAEs remained low and bal-
anced between groups (D-Vd: 9.5%; Vd: 9.3%).
Transfusions were received by 26.3% versus 20.3% of
patients (D-Vd versus Vd).  
With longer follow up, second primary malignancies
(SPMs) occurred in 10 (4.1%) patients who received D-Vd
(4 new cases following the primary analysis13 included
basal and squamous cell carcinoma, Bowen disease, and
prostate cancer) versus 1 (0.4%) patient who received Vd
(no new cases with longer follow up). 
The EORTC QLQ-C30 and EQ-5D-5L tools showed
that HRQoL was maintained during treatment for patients
in both groups who remained on the study. Significant dif-
ferences in the least squares mean changes from baseline
were not observed between D-Vd and Vd at any time for
the EORTC QLQ-C30 Global Health Status Scores or the
EQ-5D-5L Utility Score. A significant difference was
Subgroup analyses of CASTOR
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Figure 2. PFS based on prior treatment history and cytogenetic risk (ITT population). Subgroup analysis of PFS based on prior lines of therapy, prior treatment expo-
sure, refractoriness to lenalidomide at the last prior line of therapy, treatment-free interval, and cytogenetic risk. Patients with high-risk cytogenetics had any of
t(4;14), t(14;16), or del17p cytogenetic abnormalities as determined by central next-generation sequencing. Standard-risk patients had an absence of high-risk
abnormalities. PFS: progression-free survival; ITT: intent-to-treat; D-Vd: daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dexamethasone; CI:
confidence interval; NR: not reached. 
(months)
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Table 2. ORR and MRD based on prior treatment history.
# of patients ORR, # of patients MRD, n (%)b
in group n (%)a in group
10–5 10–6
Subgroup D-Vd Vd D-Vd Vd Pc D-Vd Vd D-Vd Vd Pd D-Vd Vd Pd
ITT 240 234 201 (83.8) 148 (63.2) <0.0001 251 247 29 (11.6) 6 (2.4) 0.000034 12 (4.8) 2 (0.8) 0.004763
Prior lines of therapy
1 119 109 108 (90.8) 81 (74.3) 0.0014 122 113 17 (13.9) 3 (2.7) 0.001138 8 (6.6) 2 (1.8) 0.059541
2-3 99 100 78 (78.8) 58 (58.0) 0.0022 107 106 12 (11.2) 3 (2.8) 0.013511 4 (3.7) 0 (0) 0.018130
>3 22 25 15 (68.2) 9 (36.0) 0.0294 22 28 N/A N/A N/A N/A N/A N/A
1-3 218 209 186 (85.3) 139 (66.5) <0.0001 229 219 29 (12.7) 6 (2.7) <0.0001 12 (5.2) 2 (0.9) 0.0055
Prior therapy
Bortezomib 154 153 124 (80.5) 91 (59.5) <0.0001 162 164 10 (6.2) 1 (0.6) 0.002822 5 (3.1) 0 (0) 0.007830
Lenalidomide 83 112 65 (78.3) 59 (52.7) <0.0001 89 120 7 (7.9) 2 (1.7) 0.0278 2 (2.2) 0 (0) 0.0636
Thalidomide 120 115 102 (85.0) 74 (64.3) 0.0003 125 121 16 (12.8) 4 (3.3) 0.0049 6 (4.8) 2 (1.7) 0.1544
Refractory to lenalidomide 
41 58 33 (80.5) 29 (50.0) 0.0021 45 60 4 (8.9) 0 (0) 0.008194 1 (2.2) 0 (0) 0.191319
at last prior line of therapy
Treatment-free interval   
≤12 months 125 135 96 (76.8) 66 (48.9) <0.0001 133 143 13 (9.8) 1 (0.7) 0.0002 4 (3.0) 0 (0) 0.0151
>12 months 115 99 105 (91.3) 82 (82.8) 0.0632 118 104 16 (13.6) 5 (4.8) 0.0223 8 (6.8) 2 (1.9) 0.0704
≤6 months 94 107 72 (76.6) 50 (46.7) <0.0001 101 114 8 (7.9) 1 (0.9) 0.0067 3 (3.0) 0 (0) 0.0323
>6 months 146 127 129 (88.4) 98 (77.2) 0.0139 150 133 21 (14.0) 5 (3.8) 0.0020 9 (6.0) 2 (1.5) 0.0413
Cytogenetic riske
Highf 44 47 36 (81.8) 29 (61.7) 0.2028 44 51 6 (13.6) 0 (0) 0.0018 5 (11.4) 0 (0) 0.004
Standard 118 131 100 (84.7) 84 (64.1) 0.0001 123 135 17 (13.8) 3 (2.2) 0.0003 6 (4.9) 1 (0.7) 0.0328
ORR: overall response rate; MRD: minimal residual disease; D-Vd: daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dexamethasone; ITT: intent-to-treat; N/A: not
available. Data are n (%) based on computerized algorithm.  aResponse-evaluable population. bITT population. cP-value was generated using the Cochran-Mantel-Haenszel c2 test. dP-value
was generated using the likelihood-ratio c2 test. eBiomarker risk-evaluable population. fIncludes subjects who have either del17p, t(14;16), t(4;14), or a combination of these.
Table 3. Adverse events in the safety population.
D-Vd Vd
(n=243) (n=237)
Common hematologic All-grade Grade 3 or 4 All-grade Grade 3 or 4
adverse events, n (%) ≥15% ≥5% ≥15% ≥5%
Thrombocytopenia 145 (59.7) 111 (45.7) 105 (44.3) 78 (32.9)
Anemia 69 (28.4) 37 (15.2) 75 (31.6) 38 (16.0)
Neutropenia 46 (18.9) 33 (13.6) 23 (9.7) 11 (4.6)
Lymphopenia 32 (13.2) 24 (9.9) 9 (3.8) 6 (2.5)
Common non-hematologic 
adverse events, n (%)
Peripheral sensory neuropathy 121 (49.8) 11 (4.5) 90 (38.0) 16 (6.8)
Diarrhea 85 (35.0) 9 (3.7) 53 (22.4) 3 (1.3)
Upper respiratory tract infection 76 (31.3) 6 (2.5) 43 (18.1) 1 (0.4)
Cough 68 (28.0) 0 (0.0) 30 (12.7) 0 (0.0)
Fatigue 53 (21.8) 12 (4.9) 58 (24.5) 8 (3.4)
Constipation 53 (21.8) 0 (0.0) 38 (16.0) 2 (0.8)
Back pain 47 (19.3) 5 (2.1) 24 (10.1) 3 (1.3)
Dyspnea 46 (18.9) 9 (3.7) 21 (8.9) 2 (0.8)
Edema peripheral 45 (18.5) 1 (0.4) 20 (8.4) 0 (0.0)
Pyrexia 43 (17.7) 3 (1.2) 28 (11.8) 3 (1.3)
Insomnia 42 (17.3) 2 (0.8) 36 (15.2) 3 (1.3)
Asthenia 24 (9.9) 2 (0.8) 37 (15.6) 5 (2.1)
Pneumonia 36 (14.8) 24 (9.9) 31 (13.1) 24 (10.1)
Hypertension 23 (9.5) 16 (6.6) 8 (3.4) 2 (0.8)
D-Vd: daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dexamethasone. Data are n (%). Incidences of all-grade and grade 3 or 4 adverse events 
occurring in ≥15% and ≥5% of patients in either treatment group are listed, respectively.  
observed solely at Week 21 in favor of D-Vd for the Visual
Analog Scale Score (P=0.0185). No significant differences
in EORTC QLQ-C30 global health status were observed
for median time to improvement (5.0 versus 5.1 months;
HR, 0.99; 95% CI, 0.76-1.29; P=0.9163). Similarly, no sig-
nificant differences in median time to improvement were
observed for either the EQ-5D-5L Utility Score (7.7 versus
3.5 months; HR, 0.82; 95% CI, 0.62-1.08; P=0.1469) or the
Visual Analog Scale Score (5.0 versus 5.0 months; HR, 1.03;
95% CI, 0.79-1.35; P=0.8072). 
Discussion
These data confirm that D-Vd provides significant clini-
cal benefit to patients with RRMM. D-Vd prolonged PFS,
resulting in a 69% reduction in the risk of disease progres-
sion or death versus Vd. With an additional 12 months of
follow up, responses to daratumumab deepened over time
(≥CR: 28.8%) compared with the primary analysis
(19.2%).13 Deeper responses to D-Vd were associated with
significantly higher (>4 fold) MRD-negative rates at sensi-
tivities of 10–5 and 10–6 versus Vd. We hypothesize that, as
previous studies have demonstrated a correlation between
MRD negativity and OS,21,22 this may translate into
improved OS outcomes after longer follow up for patients
treated with D-Vd. Analysis of OS is ongoing.  
There were consistent clinical benefits with D-Vd versus
Vd across subgroups based on prior lines of therapy, treat-
ment exposure, or refractory status. These were also
observed in patients regardless of time since last therapy
or cytogenetic risk, as those patient subgroups were not
evaluated in the primary analysis. Importantly, the benefit
of D-Vd was maintained in patients who received prior
bortezomib (including as their sole prior line of therapy)
and those refractory to lenalidomide at their last prior line
of therapy. Bortezomib- and lenalidomide-based combi-
nations are common MM first-line and maintenance regi-
mens. Thus D-Vd can be considered after bortezomib (if
patients are not PI-refractory) or in lenalidomide-refracto-
ry patients, which is of particular importance considering
the increased lenalidomide use as maintenance therapy in
newly diagnosed MM regardless of transplant eligibili-
ty.23,24 D-Vd significantly prolonged PFS versus Vd across all
lines of therapy with the greatest benefit achieved in
patients who received 1 prior line in comparison to those
who received 2 to 3 or >3 prior lines of therapy. Response
rates, including the rates of MRD negativity, were also
highest in patients who received 1 prior line of therapy. As
D-Vd showed the greatest benefit at first relapse, it may
represent an optimal second-line treatment for patients
after frontline lenalidomide or bortezomib.  
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Figure 3. PFS survival based on (A) cytogenetic risk and (B) MRD status. (A)
Kaplan-Meier estimates of PFS among patients evaluated for cytogenetic risk.
High-risk patients had any of t(4;14), t(14;16), or del17p cytogenetic abnormal-
ities as determined by central next-generation sequencing. Standard-risk
patients had an absence of high-risk abnormalities. (B) Kaplan-Meier estimates
of PFS among patients in the ITT population. MRD-negative status was evaluat-
ed at a sensitivity threshold of 10–5 using bone marrow aspirate samples that
were prepared using Ficoll and analyzed by the clonoSEQ® assay. PFS: progres-
sion-free survival; MRD: minimal residual disease; D-Vd: daratumumab plus
bortezomib and dexamethasone; Vd: bortezomib and dexamethasone. 
Figure 4. Time to MRD negativity in the ITT population. MRD-negative status
was evaluated over time at a sensitivity threshold of 10–5 using bone marrow
aspirate samples that were prepared using Ficoll and analyzed by the
clonoSEQ® assay. MRD: minimal residual disease; ITT: intent-to-treat; D-Vd:
daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dex-
amethasone.
A
B
The benefit of D-Vd was also maintained in patients
regardless of cytogenetic risk, as D-Vd but not Vd induced
MRD negativity in high-risk patients, suggesting that this
combination may improve historically poor outcomes in
this population.25-28
D-Vd–treated patients continued to receive daratumum-
ab monotherapy after completing 8 cycles of Vd, reflected
by the longer treatment duration (median: D-Vd, 13.4
months; Vd, 5.2 months). With longer follow up, the
depth of response in the D-Vd arm, including CR rates and
MRD negativity, continued to improve over time after
patients entered the monotherapy phase, supporting the
benefit of continued daratumumab treatment. Analyses
are ongoing to quantify the therapeutic impact of mainte-
nance therapy with single-agent daratumumab. 
This was the first randomized, phase 3 clinical trial of
RRMM with prospective MRD evaluation. MRD-nega-
tive status was associated with prolonged PFS in both
treatment groups, but D-Vd increased MRD-negative
rates at all sensitivity thresholds and evaluated sub-
groups. Additional longitudinal MRD evaluation in CAS-
TOR is ongoing and the potential benefit of daratumum-
ab-induced MRD negativity is being explored in studies
of newly diagnosed MM (ALCYONE clinicaltrials.gov
identifier 02195479; MAIA clinicaltrials.gov identifier
02252172; CASSIOPEIA clinicaltrials.gov identifier
02541383) and smoldering MM (AQUILA clinicaltrials.gov
identifier 03301220). These studies aim to further validate
MRD-negative status as a surrogate study endpoint.  
Several new agents for RRMM have been approved
based on robust clinical data, including carfilzomib29 and
ixazomib30 (second-generation PIs), pomalidomide31,32
(a third-generation immunomodulatory drug), daratumum-
ab13,14,33-35 and elotuzumab36 (monoclonal antibodies), and
panobinostat4 (a histone deacetylase inhibitor). Approvals
of many of these agents were based on superiority of PFS in
phase 3 trials. These studies are beginning to report OS out-
comes. In the ENDEAVOR study, carfilzomib and dexam-
ethasone conferred an additional OS benefit of 7.6 months
versus Vd.37 OS analysis in CASTOR is ongoing. 
Clinical trials are not usually powered to determine
optimal treatment sequencing or the most effective regi-
men for each disease subset.38 Although meta-analyses
provide useful guides for selecting treatment options,
physicians need to consider many different factors to opti-
mize individual regimens, including numbers and types of
prior regimens, duration of response to prior therapy, tox-
icities with prior therapies, disease aggressiveness, and
performance status or frailty.38,39 Based on the current find-
ings, and the findings of other studies,40 daratumumab
combined with other anti-myeloma drugs such as borte-
zomib or lenalidomide, may provide significant benefit in
patients with early relapsed MM regardless of prior treat-
ment exposure. It remains to be seen whether this trans-
lates to prolonged survival.
The safety profile of D-Vd remained unchanged with
approximately 1 year of additional follow up from the
primary analysis,13 with no new unexpected TEAEs
observed. Preliminary data indicated that adding a third
agent to Vd did not worsen HRQoL, an evaluation that
was not presented in the primary analysis. More SPMs
were reported with D-Vd versus Vd (4.1% versus 0.4%);
this rate is similar to the incidence of SPMs reported for
patients in POLLUX (5.7% for both D-Rd and Rd; manu-
script in preparation) and for RRMM patients in general
(between 1%-6%).41 At clinical cut-off, all patients in the
Vd group had discontinued or completed 8 treatment
cycles, whereas 41% of patients receiving D-Vd remained
on daratumumab treatment. Therefore, more frequent
monitoring during active treatment may explain why a
greater number of TEAEs (including grade 3 or 4 events)
and SPMs were reported with D-Vd. After 8 cycles of 
D-Vd, patients were monitored every 4 weeks during
daratumumab dosing, whereas patients who received Vd
who did not receive daratumumab monotherapy were
followed for survival via phone calls every 16 weeks fol-
lowing disease progression. 
In conclusion, the original finding of significant benefit
of D-Vd over Vd was confirmed regardless of treatment
history or cytogenetic risk. Importantly, this clinical bene-
fit was achieved without any emergent safety issues or
decline in HRQoL. These results provide further support
for the addition of daratumumab to a standard of care reg-
imen in RRMM, particularly at first relapse. The CASTOR
study is ongoing, and the feasibility of MRD negativity as
a surrogate for OS in RRMM continues to be investigated.
An analysis of OS will be conducted after 320 events are
observed.
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